Lyra Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
17.75
|
|
Average Rating
|
5.00
|
|
# Strong Buys
|
5
|
|
# Buys
|
0
|
|
# Holds
|
0
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.44
|
-0.40
|
0.04
|
9.09%
|
|
2022-06-30
|
-0.37
|
-0.43
|
-0.06
|
-16.22%
|
|
2022-03-31
|
-0.91
|
-0.54
|
0.37
|
40.66%
|
|
2021-12-31
|
-0.79
|
-1.05
|
-0.26
|
-32.91%
|
|
2021-09-30
|
-0.73
|
-0.85
|
-0.12
|
-16.44%
|
|
2021-06-30
|
-0.59
|
-0.85
|
-0.26
|
-44.07%
|
|
2021-03-31
|
-0.48
|
-0.60
|
-0.12
|
-25.00%
|
|
2020-12-31
|
-0.56
|
-0.46
|
0.10
|
17.86%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.37
|
|
2021-12-31
|
-3.35
|
|
2020-12-31
|
-20.21
|
|
2019-12-31
|
-1.32
|